Royal Bank Of Canada assumed coverage on shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) in a research note issued to investors on Thursday. The brokerage issued a sector perform rating and a $17.00 price objective on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the company. ValuEngine upgraded Akebia Therapeutics from a sell rating to a hold rating in a report on Friday, September 1st. BidaskClub upgraded Akebia Therapeutics from a sell rating to a hold rating in a report on Wednesday, August 16th. Zacks Investment Research upgraded Akebia Therapeutics from a hold rating to a buy rating and set a $16.00 target price for the company in a report on Monday, August 14th. HC Wainwright reiterated a buy rating and issued a $24.00 target price on shares of Akebia Therapeutics in a report on Wednesday, August 9th. Finally, Aegis reiterated a buy rating on shares of Akebia Therapeutics in a report on Friday, June 30th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Akebia Therapeutics currently has a consensus rating of Buy and a consensus price target of $19.88.

Shares of Akebia Therapeutics (NASDAQ AKBA) traded down 2.43% during mid-day trading on Thursday, reaching $17.30. The company’s stock had a trading volume of 1,854,298 shares. The company’s 50-day moving average price is $15.21 and its 200-day moving average price is $12.89. The stock’s market capitalization is $316.59 million. Akebia Therapeutics has a 12-month low of $7.16 and a 12-month high of $17.79.

Akebia Therapeutics (NASDAQ:AKBA) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.36. The firm had revenue of $28.52 million for the quarter, compared to analysts’ expectations of $26.50 million. On average, equities research analysts forecast that Akebia Therapeutics will post ($2.68) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/09/15/akebia-therapeutics-inc-akba-receives-new-coverage-from-analysts-at-royal-bank-of-canada.html.

In related news, SVP Michel Dahan sold 5,000 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $15.00, for a total transaction of $75,000.00. Following the completion of the transaction, the senior vice president now owns 102,224 shares in the company, valued at approximately $1,533,360. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Muneer A. Satter acquired 1,034,482 shares of the company’s stock in a transaction that occurred on Wednesday, July 5th. The shares were acquired at an average price of $14.50 per share, with a total value of $14,999,989.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 7,544 shares of company stock valued at $111,287. 7.95% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership raised its position in Akebia Therapeutics by 165.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 38,900 shares of the biopharmaceutical company’s stock valued at $559,000 after purchasing an additional 24,222 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Akebia Therapeutics during the 2nd quarter valued at $159,000. RA Capital Management LLC bought a new stake in Akebia Therapeutics during the 2nd quarter valued at $12,018,000. State Street Corp raised its position in Akebia Therapeutics by 72.9% during the 2nd quarter. State Street Corp now owns 946,888 shares of the biopharmaceutical company’s stock valued at $13,604,000 after purchasing an additional 399,160 shares in the last quarter. Finally, DAFNA Capital Management LLC raised its position in Akebia Therapeutics by 92.7% during the 2nd quarter. DAFNA Capital Management LLC now owns 135,738 shares of the biopharmaceutical company’s stock valued at $1,951,000 after purchasing an additional 65,283 shares in the last quarter. 57.62% of the stock is owned by institutional investors and hedge funds.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.